Emerging Approaches for Gastric/GEJ Cancers Take the Spotlight at ASCO GIMay 9th 2023
Emerging treatments, particularly claudin 18.2, a potential new biomarker in the HER2-negative gastric and gastroesophageal junction cancer space, were highlights of the 2023 ASCO Gastrointestinal Cancers Symposium.
Chipping Away at the Surface of Melanoma Treatment: Narrowing Down TherapiesJuly 26th 2020
A guideline from the American Society of Clinical Oncology addresses 4 clinical questions regarding approaches to systemic treatment for different types and stages of melanoma, in addition to summarizing the trials on which the recommendations were based.
Evidence Connects Polymorphisms of GSTM1 and GSTT1 to Increased RCC RiskJanuary 30th 2016
A recent meta analysis of several literature sources reveals evidence linking polymorphisms of both the GSTM1 and GSTT1 enzymes, which are involved in kidney detoxification of carcinogens to the risk of developing of renal cell carcinoma (RCC).